

Product Data Sheet

Product Name: TM-25659

Cat. No.: GC33782

Chemical Properties

Cas. No. 260553-97-7

SMILES CC1=C(C2=CC=CN=C2)C=C3C(N(CC4=CC=C(C5=CC=CC=C5C6=NN=NN6)C=C4)C(CCCC)=N3)=N1


Formula $C_{30}H_{28}N_8$ M.Wt 500.6

Solubility DMSO : ≥ 135 mg/mL (269.68 mM); Water : < 0.1 mg/mL (insoluble) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

TM-25659 is a TAZ modulator. Anti-osteoporotic and anti-obesity activities[1].

TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPAR γ -mediated adipocyte differentiation by facilitating PPAR γ suppression activity of TAZ[1]. TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

osteoblast differentiation[1].|| Cell Proliferation Assay[1]||Cell Line:|3T3-L1 cells|Concentration:|2, 10, 20, 100 µM|Incubation Time:|6 days|Result:|TM-25659 acted as a suppressor of PPARγ-dependent adipocyte differentiation[1].

TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model[1].TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t_{1/2} of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h⁻¹×kg⁻¹ and the volume of distribution at steady-state (1.91 L×h⁻¹×kg⁻¹) is larger than the volume of total body fluids[1].|| Animal Model:|C57BL6 mice (4- to 6-week-old)|[1]|Dosage:|50 mg/kg|Administration:|i.p., every other day for 2 weeks|Result:| || Animal Model:|Adult male Sprague-Dawley rats|[1]|Dosage:|10 mg/kg|Administration:|i.v (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h)|Result:|

[1]. Jang EJ, et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol. 2012 Mar;165(5):1584-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA